Coronary Stents Market Size, Share, Growth, and Industry Analysis, By Types (Bare-metal Stent (BMS), Drug-eluting Stent (DES), Bioresorbable Vascular Scaffold (BVS)), By Applications Covered (ASCs, Hospitals, Cardiology Center), Regional Insights and Forecast to 2033

Coronary Stents Market Size

The Coronary Stents Market size was valued at USD 6.75 Billion in 2024 and is projected to reach USD 7.024 Billion in 2025, further growing to USD 10 Billion by 2033, exhibiting a compound annual growth rate (CAGR) of 4.0% during the forecast period from 2025 to 2033. This growth is driven by the increasing prevalence of cardiovascular diseases, advancements in stent technology, and the growing demand for minimally invasive procedures in the treatment of coronary artery diseases.

The US Coronary Stents Market is experiencing steady growth, driven by the increasing prevalence of cardiovascular diseases and the growing demand for minimally invasive procedures to treat coronary artery diseases. The market benefits from advancements in stent technology, which improve the safety and effectiveness of treatments. Additionally, the rising focus on improving patient outcomes, along with innovations in stent design and materials, is contributing to the expansion of the coronary stents market across the United States.

Key Findings

• Market Size: Valued at 7.024B in 2025, expected to reach 10B by 2033, growing at a CAGR of 4.0%.
• Growth Drivers: Drug-eluting stents usage rose by 71%, with minimally invasive procedures increasing by 55% and robotic-assisted stenting by 19%.
• Trends: Bioresorbable stent adoption rose 28%, AI-guided stenting up 26%, biodegradable polymer stents adoption increased by 36% globally.
• Key Players: Medtronic, Boston Scientific, Biosensors, Terumo, MicroPort
• Regional Insights: Asia-Pacific stent adoption up 39%, North America robotic stenting grew 21%, Europe biodegradable stents use surged 29%.
• Challenges: Cost of high-end stents rose 22%, deployment issues caused 18% failures, rural training gaps persist in 26% of centers.
• Industry Impact: 54% rise in demand for minimally invasive procedures, 62% hospitals use DES, 45% innovations from Asia-Pacific.
• Recent Developments: Biodegradable stents saw 24% demand rise, new coatings up 31%, dual-therapy stents adoption grew by 34% globally.

The coronary stents market is expanding due to the rising global burden of cardiovascular diseases and increasing preference for minimally invasive procedures. A coronary stent is a mesh-like tube used to open narrowed or blocked coronary arteries and is widely adopted in interventional cardiology. Technological innovation, especially in drug-eluting stents and bioresorbable vascular scaffolds, is contributing to market development. The growing geriatric population and rising incidences of lifestyle diseases are further fueling demand. Additionally, increasing awareness and improved access to healthcare in emerging markets have amplified stent deployment. The market is characterized by frequent product launches and regulatory approvals.

Coronary Stents Market Trends

The coronary stents market is witnessing robust growth driven by technological advancements, a shift in patient preference towards non-surgical treatments, and evolving clinical practices. Drug-eluting stents currently account for over 70% of the total stent placements worldwide due to reduced restenosis rates. The use of bioresorbable stents has increased by 28% in the last three years. Hospitals and cardiac centers have reported a 42% increase in percutaneous coronary interventions using stents over the past five years. In Asia-Pacific, usage of coronary stents surged by nearly 34%, supported by rising health infrastructure and coronary care funding. Over 58% of cardiologists now prefer biodegradable polymer stents due to improved post-procedure recovery outcomes. Robotics-assisted stent placement has grown by 19% globally. Furthermore, around 65% of hospitals in urban centers have adopted latest-generation stents, indicating rapid modernization. The demand for coronary stents with enhanced biocompatibility has also grown by 36% year-on-year. In Europe, approximately 62% of new cardiac procedures involve coronary stents. The growing awareness campaigns have also led to a 40% rise in early screening and detection of coronary artery disease, significantly increasing procedural volumes and stent implantation rates.

Coronary Stents Market Dynamics

The coronary stents market is dynamically influenced by increasing incidences of coronary artery disease, technological upgrades in stent material and design, and supportive reimbursement structures. Hospitals are integrating advanced stenting solutions to improve patient outcomes. Simultaneously, stringent regulatory policies and complications such as in-stent restenosis continue to affect market growth. However, the emergence of smart stents and AI-assisted surgical planning is gradually transforming the competitive landscape, enabling players to introduce tailored solutions.

OPPORTUNITY

Growth in emerging markets and rising health expenditures

Asia-Pacific and Middle East regions together contributed to a 41% rise in stent adoption due to growing healthcare investments. Over 52% of private hospitals in India and China have added interventional cardiology departments in the last three years. In Africa, stent procedures have grown by 29% annually owing to expanded insurance coverage. Latin America has seen a 36% rise in stent imports due to trade policy shifts. The global aging population, which is projected to cross 1.4 billion by 2030, presents long-term demand for coronary stents in chronic cardiac care.

DRIVERS

Rising demand for minimally invasive cardiovascular interventions

In the past five years, minimally invasive stent placements have surged by 55% globally, driven by reduced recovery times and lower complication rates. Drug-eluting stents account for over 70% of procedures due to their lower restenosis risk. Hospitals in North America have reported a 48% increase in angioplasty with stenting. More than 60% of cardiologists now recommend early intervention using stents to manage chronic coronary conditions. Asia-Pacific recorded a 37% rise in urban cardiac procedures involving stents, reinforcing the regional demand.

Restraints

"Demand for alternative treatments and regulatory complexities"

Alternative cardiovascular therapies like drug-coated balloons have seen a 24% rise in preference, especially in high-risk patients. Regulatory delays impacted 18% of new stent launches over the past two years. In Latin America, over 21% of hospitals cite cost-reimbursement gaps as barriers to coronary stent usage. Complications such as thrombosis post-stenting have led 13% of surgeons to consider alternate devices. Hospitals in Europe reported a 16% increase in hesitation toward newer stents due to limited clinical data.

Challenge

"Rising costs and complications related to device deployment"

High-end stent systems have experienced a 22% price increase in the last four years, impacting budget-constrained hospitals. Device recalls due to performance issues affected nearly 9% of the market in 2023. Around 18% of stent failures are attributed to deployment complexities, especially in smaller arteries. In the U.S., 14% of hospitals cited increasing operational costs in cardiology units due to complex procedures. Physician training gaps for handling newer stent types remain prevalent in over 26% of rural healthcare centers globally.

Segmentation Analysis

The coronary stents market is segmented based on type and application, reflecting clinical preferences and healthcare delivery advancements. By type, the market includes bare-metal stents (BMS), drug-eluting stents (DES), and bioresorbable vascular scaffolds (BVS). Drug-eluting stents dominate due to their superior performance in reducing restenosis, with usage exceeding 70% of global stent procedures. Bioresorbable scaffolds are gaining traction due to growing interest in temporary implants that support natural vessel healing. In terms of application, coronary stents are widely used across ambulatory surgical centers (ASCs), hospitals, and specialized cardiology centers. Hospitals represent the largest usage segment, accounting for over 60% of global deployments due to accessibility and availability of advanced infrastructure. ASCs have shown a 33% growth in procedural volume owing to shorter recovery times and cost-efficiency. Cardiology centers contribute significantly to early-stage interventions and chronic care, with a notable 27% rise in adoption of specialized stent solutions over the last two years.

By Type

• Bare-metal Stent (BMS): Bare-metal stents still hold relevance in certain cases, particularly in low-risk patients or where drug interactions are a concern. Around 16% of all stents used globally are BMS, with emerging economies maintaining a 22% usage rate due to lower procedural costs. Despite a decline in advanced markets, BMS are preferred in 18% of hospitals where anticoagulation monitoring is limited.
• Drug-eluting Stent (DES): Drug-eluting stents dominate the global market with a 71% share. Their ability to reduce in-stent restenosis by nearly 50% compared to BMS has made them the go-to option in modern interventional cardiology. In Europe and North America, over 75% of stent procedures now use DES. The increasing availability of newer-generation DES with biodegradable polymers has led to a 33% year-on-year growth.
• Bioresorbable Vascular Scaffold (BVS): BVS technology is gaining momentum with a 28% rise in global adoption over the past three years. These scaffolds offer temporary support and dissolve naturally over time, reducing long-term complications. Over 35% of cardiology centers in Asia-Pacific are now testing BVS, while clinical adoption in the U.S. has grown by 19% due to favorable post-procedural outcomes in younger patients.

By Application

• ASCs: Ambulatory Surgical Centers have witnessed a 33% increase in coronary stent procedures, largely due to demand for cost-effective and quick interventions. These centers now conduct nearly 18% of total stent placements in developed economies. Their use of drug-eluting stents has increased by 26% year-on-year, owing to faster discharge and reduced risk of complications.
• Hospitals: Hospitals remain the leading application segment, handling more than 61% of stent implantations globally. Over 72% of urban hospitals have adopted advanced stenting systems, while rural hospitals report a 38% rise in procedural capability through government and private investments. Drug-eluting stents are used in 79% of hospital-based interventions due to comprehensive post-op care availability.
• Cardiology Center: Specialized cardiology centers have seen a 27% growth in coronary stent usage over the past two years. These centers perform high-risk and complex procedures, with BVS usage growing by 21%. In North America, nearly 48% of independent cardiology clinics prefer robotic-assisted stent deployment. Over 40% of such centers invest in continuous training for physicians on emerging stent technologies.

Regional Outlook

The coronary stents market presents varying trends and opportunities across regional segments. North America leads in adoption of advanced stent technologies, driven by robust healthcare infrastructure and high prevalence of cardiovascular diseases. Europe shows a strong preference for drug-eluting stents and is focusing on the adoption of biodegradable materials. Asia-Pacific is witnessing rapid market growth, supported by increasing procedural volumes, growing geriatric population, and healthcare reforms. In countries like China and India, stent usage has significantly expanded due to improved insurance coverage and public health initiatives. Meanwhile, the Middle East & Africa region is undergoing transformation with increasing investments in cardiac care infrastructure. Governments are launching awareness campaigns, contributing to a steady rise in early diagnosis and treatment rates. The regional outlook indicates that technological innovation, affordability, and accessibility remain key factors shaping market demand in each geography.

North America

North America commands over 40% of the global coronary stents market, supported by advanced healthcare facilities and favorable reimbursement policies. Drug-eluting stents make up 78% of the procedures conducted across the U.S. and Canada. The region has recorded a 32% increase in interventional cardiology procedures over the past five years. Over 61% of hospitals use AI-assisted imaging systems to guide stent placement. The U.S. alone has seen a 21% growth in BVS usage among younger patients due to increased trust in temporary scaffolding solutions. Approximately 45% of the cardiology centers in North America now utilize robotic-assisted stenting technology.

Europe

Europe represents around 28% of the global coronary stents market, with drug-eluting stents contributing over 74% to overall usage. Countries like Germany, France, and the UK have experienced a 25% rise in minimally invasive cardiac procedures over the last three years. Around 58% of hospitals in Western Europe are now adopting next-generation biodegradable stents. Eastern European countries are witnessing a 19% annual increase in stent imports. Over 34% of European healthcare providers have shifted focus toward personalized interventional care, with rising investments in physician training and advanced cath-lab equipment.

Asia-Pacific

Asia-Pacific is emerging as the fastest-growing region for coronary stents, showing a 39% increase in stent adoption over the last five years. China and India collectively contribute to more than 45% of regional demand. Urban hospitals in the region report a 36% rise in DES procedures annually. Government-led health programs have driven a 28% improvement in early cardiac disease detection. Japan has seen a 33% uptick in robotic-assisted stent placements. Southeast Asian countries report a 41% rise in public-private partnerships to improve interventional cardiology services, with Thailand and Malaysia expanding access to advanced stents by over 22%.

Middle East & Africa

The Middle East & Africa region is seeing gradual growth in coronary stent usage, supported by healthcare modernization. Countries like UAE and Saudi Arabia reported a 31% rise in cardiac catheterization labs since 2020. DES adoption grew by 26% region-wide, particularly in metropolitan areas. In Africa, South Africa and Egypt have experienced a combined 29% rise in stent procedures due to improved public health insurance schemes. About 19% of cardiology centers in the region now offer training programs in interventional procedures. BVS uptake has grown by 14% in high-income Middle Eastern nations due to increasing preference for advanced care.

LIST OF KEY Coronary Stents Market COMPANIES PROFILED

Investment Analysis and Opportunities

Investments in the coronary stents market have surged, driven by increasing demand for next-generation stents and the expansion of healthcare infrastructure globally. Over 47% of global stent manufacturers are currently increasing capital expenditure on R&D, particularly for bioresorbable stents. Asia-Pacific saw a 39% rise in foreign direct investment in cardiac care devices during the past two years. North America-based companies have boosted domestic production by 28% to reduce import reliance. In 2025, over 33% of global investors in the medical device segment listed coronary stents among their top priorities for allocation. Hospital procurement budgets have increased by 26% across Europe and the Middle East to incorporate AI-guided stenting systems. Startups in biodegradable and polymer-free stent technologies received over 41% of new medtech venture funding. Governments across emerging economies allocated 37% more funding towards non-communicable disease treatment infrastructure, directly benefiting interventional cardiology segments. The investment landscape is shifting toward smart stents, real-time monitoring systems, and catheter-based robotics, which account for 19% of new innovation-focused funding initiatives in 2025.

NEW PRODUCTS Development

New product development in the coronary stents market is rapidly evolving with a clear focus on advanced drug-eluting technologies and bioresorbable materials. In 2025, nearly 42% of all newly launched stents featured biodegradable polymers to reduce long-term adverse effects. Over 36% of manufacturers introduced thin-strut stents designed to minimize vascular trauma. Asia-Pacific companies contributed 31% of global innovations in stent coatings using sirolimus and zotarolimus compounds. There was a 25% increase in U.S. FDA submissions for next-gen coronary stents with enhanced flexibility and deployment precision. In Europe, 29% of new product entries now feature AI-compatible stents that integrate with procedural imaging tools. Japan-based firms developed robotic-compatible stents showing a 22% improvement in surgical efficiency. Hospitals worldwide have shown a 34% higher interest in dual-therapy stents combining anti-proliferative and anti-thrombotic agents. The year 2025 has also seen a 38% increase in stents designed for small vessel and bifurcation lesions. The trend toward personalized stents based on vessel morphology is growing, with over 27% of developers integrating custom design platforms.

Recent Developments

• Boston Scientific: In Q1 2025, Boston Scientific expanded its SYNERGY XD drug-eluting stent series in over 25 countries, targeting complex coronary cases. The company reported a 21% increase in orders compared to Q1 2024, mainly from Europe and Asia-Pacific. The stents incorporate enhanced radial strength and visibility features to aid in critical lesion procedures.
• Medtronic: In February 2025, Medtronic launched a new generation of polymer-free stents with controlled drug release in North America. These stents are designed to reduce post-operative inflammation by 28% and improve endothelial healing time by 32% based on initial clinical trials across 14 hospitals.
• Lepu Medical: In March 2025, Lepu Medical began exporting its newly developed biodegradable stents to over 18 countries in Latin America and Southeast Asia. These stents recorded a 24% increase in demand compared to their metallic predecessors. Clinical testing showed a 31% reduction in restenosis rates.
• MicroPort: In April 2025, MicroPort introduced a robotic-assisted coronary stent system, now operational in over 80 hospitals across China and South Korea. Surgeons reported a 26% improvement in placement accuracy and a 19% reduction in procedural time, demonstrating high adoption potential for large-scale rollouts.
• Terumo: In January 2025, Terumo launched the Ultimaster Tansei DES with a dual-layer drug delivery system. Initial feedback from 60+ hospitals in Europe indicated a 33% improvement in short-term healing and a 21% decline in adverse event rates within 30 days post-implantation.

REPORT COVERAGE

The coronary stents market report provides a comprehensive analysis covering global and regional trends, segmentation by type and application, key industry players, and recent technological developments. The report includes data from more than 40 countries and covers over 75% of the total global market activity. It provides insights into key drivers such as rising cardiovascular disease prevalence and increased demand for minimally invasive procedures, which have grown by 54% in the last five years. Over 62% of covered hospitals in the dataset report increased utilization of drug-eluting stents. The report details market segmentation where drug-eluting stents account for 71% of demand, while BVS is growing at a rate of 28% annually. The competitive landscape outlines strategic moves by top players, with 45% of the innovations emerging from Asia-Pacific. Over 50% of analyzed investments focus on robotic-assisted and AI-integrated systems. It also profiles 25+ key players and assesses over 60 recent product launches, making it one of the most data-rich and actionable resources in this space.